Wockhardt Q3 Results: Pharma Major Swings Back To Profit As Expenses Fall

On the operating side, Ebitda jumped to Rs 128 crore from Rs 37 crore, while margin expanded to 17.8% from 5.3%.

Wockhardt Ltd. plans to launch Miqnaf in the next three months. (Photo source: Company website)

Wockhardt Ltd. swung back to profit in the quarter ended December 2024, with a bottom line of Rs 14 crore, according to an exchange filing on Friday.

Also Read: Wockhardt Sees New Drugs To Fight Superbugs As Next Growth Driver

Wockhardt's share price was trading 2% higher at Rs 1,618 apiece at 2:15 p.m. on the NSE, compared to a 0.39% drop in the benchmark Nifty 50. A day prior, the stock spiked 1.5% after the results.

The stock has risen 262.05% in the last 12 months. Total traded volume so far in the day stood at 0.54 times its 30-day average. The relative strength index was at 58.81.

Also Read: Q3 Results Updates: LIC, M&M, Mazagon Dock Profit Surges; NHPC Profit Slips, Ola Electric Loss Widens

Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit. Feel free to Add NDTV Profit as trusted source on Google.
WRITTEN BY
Sai Aravindh
Sai Aravindh is a desk writer at NDTV Profit, where he covers business and ... more
GET REGULAR UPDATES
Add us to your Preferences
Set as your preferred source on Google
Google Badge